Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Ono Licenses Salirasib from Concordia
September 13, 2010
- BI Applies for Dabigatran for SPAF in Japan
September 13, 2010
- ViiV Starts Full-Scale Operations in HIV Area in Japan
September 13, 2010
- Daiichi Sankyo Confident About Differentiation of Edoxaban
September 13, 2010
- Novartis Enhances Supply of Scientific Information
September 13, 2010
- Eisai's PAR-1 Antagonist Appears Promising as New Drug for Atherothrombosis
September 13, 2010
- Takeda Licenses Cell Culture-Based Flu Vaccine Technology from Baxter
September 13, 2010
- Astellas Confirms YM150's Safety for AF in PIIa in Japan/Asia
September 13, 2010
- Takeda Completes Computerization in Synthetic Study Dept.
September 13, 2010
- MSD to Enter PIII for Betrixaban in 2011
September 13, 2010
- RaQualia Licenses Acid Pump Antagonists to CJ Cheil Jedang
September 13, 2010
- Genetic Variability Does Not Affect Responses to Ticagrelor: PLATO Study Subanalysis
September 13, 2010
- Novartis Makes Alcon Consolidated Subsidiary
September 13, 2010
- Evidence on Diovan Accumulated in Japanese Patients
September 13, 2010
- Daiichi Sankyo Revises 1st Half FY2010 Business Forecasts Upward
September 13, 2010
- ACOS Focuses on Therapeutic Cancer Vaccines
September 13, 2010
- Fujifilm to Enter into Capital Partnership with J-TEC
September 13, 2010
- Sutent Does Not Extend OS in NSCLC in PIII: Pfizer
September 13, 2010
- New PFSB Director General to Place Top Priority on Prevention of Drug-Induced Health Damage
September 13, 2010
- Lilly Applies for Gemzar for Ovarian Cancer Based on Data from Public Domain
September 13, 2010
ページ
The launch of Elevidys has opened the door to gene therapy for DMD, but research into new treatments is already…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…